Posted on 12 February 2015
The Alzheimer's Drug Discovery Foundation (ADDF) and Pfizer's Centers for Therapeutic Innovation (CTI) announced a collaboration designed to advance the development of new small-molecule drugs for Alzheimer's disease and related dementias.
As part of the first-of-its kind collaboration in Alzheimer's, the ADDF and CTI will jointly invest in translational research projects, with a focus on novel Alzheimer's drug targets.
|Searching for more deal information? Current Partnering offers the following options:
- CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
- Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
- CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top pharmaceutical companies
View: Top biotech companies
Reports: Browse our extensive deal making report portfolio